Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.52 |
| ▸ | PREP | P48147 | 4/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16004387 | 1.00 | AAK1 (0.52) | AAK1PREPHDAC1CHRM2CHRM1 | |
| SCHEMBL18993181 | 1.00 | AAK1 (0.52) | AAK1PREPHDAC1CHRM2CHRM1 | |
| SCHEMBL2707662 | 1.00 | AAK1 (0.52) | AAK1PREPHDAC1CHRM2CHRM1 | |
| SCHEMBL18993180 | 0.92 | PREP (0.47) | AAK1PREPHDAC1CHRM2CHRM1 | |
| SCHEMBL16541368 | 0.92 | PREP (0.47) | AAK1PREPHDAC1CHRM2CHRM1 | |
| SCHEMBL20462077 | 0.92 | PREP (0.47) | AAK1PREPHDAC1CHRM2CHRM1 | |
| SCHEMBL15406118 | 0.87 | PREP (0.42) | AAK1PREPHDAC1CHRM2CHRM1 | |
| SCHEMBL15406119 | 0.87 | PREP (0.42) | AAK1PREPHDAC1CHRM2CHRM1 | |
| SCHEMBL14948527 | 0.85 | PREP (0.46) | AAK1PREPCHRM2CHRM1CHRM3 | |
| SCHEMBL9957849 | 0.84 | AAK1 (0.50) | AAK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| EP-2855478-B1 | LEDIPASVIR D-TARTRATE | GILEAD PHARMASSET LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8273341-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| WO-2012087596-A1 | COMBINATIONS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2430014-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110306541-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306541-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | AAK1 4110/4885PREP 942/4885HDAC1 1242/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | AAK1 3098/4885PREP 440/4885HDAC1 1234/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | AAK1 3098/4885PREP 440/4885HDAC1 1234/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | AAK1 3098/4885PREP 440/4885HDAC1 1234/4885 |
| US-10456414-B2 | Methods for treating HCV | HAVCR2, HCCS, LIPC | AAK1 4110/4885PREP 942/4885HDAC1 1242/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | AAK1 3098/4885PREP 440/4885HDAC1 1234/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | AAK1 3098/4885PREP 440/4885HDAC1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.